Funding push to pharma R&D critical for unleashing next phase of growth
The industry is at an inflection point and it awaits mega investments, the right government policies, and the creation of a strong ecosystem to propel innovation
The industry is at an inflection point and it awaits mega investments, the right government policies, and the creation of a strong ecosystem to propel innovation
ImmunoACT has a portfolio of CAR-T therapy assets under various development stages for the treatment of multiple autoimmune diseases and oncology indications.
It is the first blood test able to detect early-stage Breast Cancer with high accuracy in women above the age of 40 years
Premas Biotech is the developer of the technology for the Covid-19 vaccine and a shareholder in Oravax Medical
Betting big on talent, resources, and the ecosystem required for innovation and enterprise, Prime Minister Narendra Modi invited stakeholders to ideate in India, innovate in India and Make in India for the world
First-of-its-kind Incubator will support companies poised to deliver breakthrough applications in genomics and multiomics
Nelarabine is in a class of medications called antimetabolites
Six-months follow-up of prevention trial showed 83% reduced risk of symptomatic Covid-19, with no severe disease or deaths
A CRISIL study of 207 pharmaceutical companies that account for 55% of the Rs 3.2 lakh crore-a-year sector revenue indicates as much.
Viyash has ten manufacturing facilities in India with a combined capacity of 2000 KL as well as one formulation facility in the US, and is now one of India’s leading mid-tier integrated API and formulation players
Subscribe To Our Newsletter & Stay Updated